Keeping expanded access programs in context

Muscle Nerve. 2023 May;67(5):337-338. doi: 10.1002/mus.27802. Epub 2023 Mar 9.
No abstract available

Keywords: FDA approval; amyotrophic lateral sclerosis; biomarker; clinical trial; expanded access program.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Amyotrophic Lateral Sclerosis*
  • Humans
  • United States
  • United States Food and Drug Administration